| Literature DB >> 36090453 |
Yushan Wang1, Yi Xiang2, Qiaoqiao Tian1, Wei Luo3, Hao Fan1, Peng Ren1, Zhi Lv1, Jia Lv1, Junjun Bai1, Xiaochen Qiao1, Yi Feng1.
Abstract
Purpose: To examine the effects of 3D printing model in total en bloc spondylectomy (TES).Entities:
Mesh:
Year: 2022 PMID: 36090453 PMCID: PMC9453004 DOI: 10.1155/2022/7907191
Source DB: PubMed Journal: J Healthc Eng ISSN: 2040-2295 Impact factor: 3.822
General information of patients in 3D group.
| Age (y) | Gender | Diagnosis | Area | Tomita score/Enneking stage | SA | OT (min) | BL (ml) | SSI | CSF leak | Doe | Rr | Tms | Recurrence | Os | VAS score | ASIA grade | FT (m) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre | 1w-po | 6m-po | Pre | 6m-po | ||||||||||||||||
| 60 | M | DL-BCL | T7 | B5 | Posterior | 300 | 1500 | − | − | + | R0 | − | − | DOD | 5 | 1 | 2 | C | E | 8 |
| 68 | F | M | L2 | 3 | Posterior | 430 | 9000 | − | − | + | R1 | + | + | DOD | 6 | 2 | 1 | C | E | 40 |
| 50 | F | M | T5 | 5 | Posterior | 300 | 2000 | − | − | + | R0 | − | − | DOD | 5 | 3 | 0 | E | E | 43 |
| 76 | M | Chondrosarcoma | T3, 4, 5 | B6 | Posterior | 260 | 1100 | − | − | − | R0 | + | − | NED | 3 | 1 | 0 | D | E | 24 |
| 60 | F | M | T11 | 5 | Posterior | 210 | 1300 | − | + | − | R0 | + | − | NED | 7 | 3 | 1 | E | E | 32 |
| 56 | M | Osteosarcoma | T3 | B5 | Posterior | 240 | 800 | − | − | − | R0 | − | + | NED | 5 | 2 | 1 | E | E | 24 |
| 63 | M | M | C5, 6 | 4 | Combined | 390 | 2300 | − | + | + | R1 | − | − | NED | 5 | 4 | 0 | E | E | 20 |
| 54 | M | M | L2 | 3 | Posterior | 260 | 3500 | − | − | − | R0 | − | − | NED | 6 | 3 | 1 | D | E | 18 |
| 48 | F | M | T10 | 5 | Posterior | 220 | 900 | − | − | − | R0 | − | − | DOD | 7 | 2 | 1 | D | E | 18 |
| 50 | M | Plasmacytoma | T11 | B5 | Posterior | 210 | 700 | − | − | − | R0 | − | − | NED | 7 | 2 | 0 | D | E | 17 |
| 56 | F | M | T7 | 5 | Posterior | 200 | 1000 | − | + | − | R0 | + | − | NED | 7 | 3 | 1 | E | E | 16 |
| 26 | F | M | T10 | 3 | Posterior | 230 | 2600 | − | − | − | R1 | − | − | NED | 6 | 2 | 0 | E | E | 16 |
| 51 | F | Plasmacytoma | T8 | B5 | Posterior | 220 | 1000 | − | − | − | R0 | − | − | NED | 7 | 3 | 0 | C | E | 15 |
| 73 | F | Chondrosarcoma | L1 | B4 | Posterior | 300 | 900 | − | − | − | R0 | + | + | DOD | 5 | 2 | 0 | E | E | 9 |
| 57 | M | CO | T3, 4, 5 | B6 | Posterior | 330 | 2000 | − | − | − | R0 | + | − | NED | 6 | 2 | 0 | D | E | 13 |
| 55 | F | LL | L4 | B5 | Posterior | 270 | 1500 | + | − | − | R0 | + | − | DOC | 8 | 4 | 2 | C | D | 7 |
| 47 | M | M | T3 | 5 | Posterior | 240 | 800 | − | − | + | R0 | − | − | NED | 8 | 2 | 0 | E | E | 13 |
| 47 | F | M | T12 | 5 | Posterior | 250 | 1500 | − | − | − | R0 | − | − | NED | 5 | 1 | 1 | E | E | 12 |
| 53 | F | Plasmacytoma | T11 | B5 | Posterior | 230 | 1200 | − | − | − | R0 | + | − | NED | 7 | 3 | 1 | D | E | 12 |
SA: surgical approach; OT: operation time; BL: blood loss; SSI: surgical site infection; CSF leak: cerebrospinal fluid leak; Doe: damage of envelope; Rr: resection range; Tms: titanium mesh subsidence; Os: oncology status; pre: preoperation; po: postoperation: 1w-po: 1 week postoperation; 6m-po: 6 months postoperation; combined: a combined anterior and posterior approach; DOC: death of cancer related complications; DOD: death of dyscrasia; NED: No Evidence of Disease; DL-BCL: Diffuse large B cell lymphoma; M: Metastatic tumors; CO: Chondroblastic osteosarcoma; LL: Lymphocytic leukemia.
General information of patients in non-3D group.
| Age (y) | Gender | Diagnosis | Area | Tomita score/Enneking stage | SA | OT (min) | BL (ml) | SSI | CSF leak | Doe | Rr | Tms | Recurrence | Os | VAS score | ASIA grade | FT (m) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre | 1w-po | 6m-po | Pre | 6m-po | ||||||||||||||||
| 56 | M | Osteosarcoma | T3 | B5 | Posterior | 400 | 2500 | − | − | + | R0 | − | − | NED | 6 | 3 | 1 | D | E | 27 |
| 53 | F | Plasmacytoma | T11 | B5 | Posterior | 270 | 2500 | − | − | + | R1 | + | − | NED | 4 | 2 | 0 | E | E | 36 |
| 48 | M | M | T5 | 5 | Posterior | 280 | 2000 | − | + | R1 | − | + | DOC | 7 | 3 | 3 | D | E | 9 | |
| 74 | M | M | L1 | 4 | Posterior | 330 | 3500 | − | − | + | R0 | − | − | NED | 5 | 1 | 1 | E | E | 32 |
| 60 | F | M | L3 | 2 | Posterior | 350 | 3000 | − | + | R0 | + | − | NED | 5 | 2 | 1 | E | E | 25 | |
| 51 | M | Plasmacytoma | T11 | B4 | Posterior | 270 | 1800 | − | − | R0 | − | − | NED | 4 | 1 | 1 | E | E | 22 | |
| 60 | F | M | T8, 9 | 3 | Posterior | 340 | 3300 | − | + | + | R1 | + | − | NED | 5 | 3 | 1 | E | E | 20 |
| 55 | F | M | L3 | 5 | Posterior | 330 | 2700 | − | − | + | R1 | − | + | DOC | 6 | 3 | 2 | E | E | 15 |
| 33 | F | M | T8 | 2 | Posterior | 240 | 1200 | − | − | + | R0 | − | − | NED | 5 | 2 | 2 | E | E | 28 |
| 66 | M | M | T12 | 5 | Posterior | 270 | 1600 | − | − | R1 | + | − | DOC | 7 | 3 | 2 | D | E | 22 | |
| 63 | F | M | T10 | 4 | Posterior | 240 | 1600 | − | − | + | R1 | − | − | DOD | 6 | 2 | 2 | D | E | 8 |
| 62 | M | M | L4 | 5 | Posterior | 330 | 3500 | − | + | + | R1 | − | − | NED | 7 | 2 | 1 | E | E | 30 |
| 46 | M | M | T12 | 5 | Posterior | 250 | 1600 | − | − | R0 | + | − | NED | 5 | 3 | 2 | E | E | 33 | |
| 51 | F | M | L2 | 4 | Posterior | 320 | 2800 | − | + | + | R1 | + | − | DOC | 5 | 2 | 1 | E | E | 30 |
| 74 | F | M | T4 | 3 | Posterior | 230 | 1500 | − | − | R0 | + | − | DOC | 7 | 2 | 2 | E | E | 16 | |
| 20 | M | Invasive GCTB | L2 | B5 | Posterior | 260 | 2700 | − | − | + | R0 | − | − | NED | 5 | 2 | 0 | E | E | 34 |
| 67 | M | M | T11 | 5 | Posterior | 240 | 1800 | − | − | + | R1 | − | − | NED | 8 | 3 | 2 | B | D | 28 |
| 70 | M | M | T5 | 5 | Posterior | 220 | 1500 | − | − | R0 | − | + | DOC | 5 | 2 | 3 | D | E | 11 | |
| 80 | F | Fibrosarcoma | L4 | B5 | Posterior | 300 | 2900 | − | + | R0 | + | + | NED | 4 | 1 | 1 | C | D | 18 | |
| 67 | M | M | L1 | 5 | Posterior | 270 | 2000 | − | − | + | R0 | − | − | DOC | 7 | 2 | 1 | E | E | 30 |
| 56 | F | M | T9 | 2 | Posterior | 250 | 1600 | − | − | R0 | − | − | NED | 6 | 2 | 2 | E | E | 25 | |
| 56 | M | Chondrosarcoma | T3, 4 | B6 | Posterior | 300 | 2800 | − | − | + | R1 | + | + | DOC | 8 | 3 | 5 | D | D | 8 |
GCTB: giant cell tumor of bone.
Figure 1(a) The extent of bone destruction and bone tumor invasion at each level was captured by CT and MRI. (b) The reconstructed 3D images were fused to show the anatomical relationships. The spinal cord was shown in yellow. The extent of tumor invasion was shown in red. The extent of bone destruction was shown in blue. (c) 3D images were printed into the PLA model. (d) Gross view of the tumor resected and postoperative X-rays.
Figure 2A 76-year-old male with chondrosarcoma diagnosed by needle biopsy. (a) MRI in the sagittal plane showed tumor invasion at T3, 4, and 5 levels. Transverse MRI showed that the tumor penetrated mainly to the left side of the vertebrae with left nerve root involved. The tumor showed low signal in T1 phase and medium high signal in T2 phase. (b) CT showed significant bone destruction. (c) The 3D printed model showed in detail the location and size of the tumor, the extent of its invasion in the bone tissue and its anatomic relationship with surrounding structures. (The tumor is in red). (d) The tumors completely removed during the operation were consistent with the 3D printed model in morphology, position, and other aspects. The capsule of the tumor was not destroyed. (e) On X-ray, we can see the gross structure of the lesion. The vertebrae and tumor were removed completely. (f) Postoperative X-ray showed complete removal of the lesion and good internal fixation. (g) Radiographs showed no local recurrence and solid internal fixation one year after surgery.
Figure 3Cancer-specific survival (CSS) of 41 patients who underwent TES for malignant spinal tumor. In 3D group, the 3-year CSS rate after TES was 59% and estimated median CSS time after TES was 40.0 months. In non-3D group, the 3-year CSS rate after TES was 48% and estimated median CSS time after TES was 30.0 months. There was no statistical difference in survival time between the two groups (P > 0.05).
Data statistics and analysis.
| Factor | Condition | 3D group | Non-3D group | |
|---|---|---|---|---|
| Gender | Male | 8 | 12 | |
| Female | 11 | 10 | ||
| Year | 55 ± 11 | 58 ± 14 | ||
| Operation time (min) | 268 ± 62 | 286 ± 47 | ||
|
| ||||
| Blood loss (ml) | 1874 ± 1872 | 2291 ± 716 |
| |
|
| ||||
| Complications | Surgical site infection | 1 (5.2%) | 0 | |
| Cerebrospinal fluid leak | 3 (15.7%) | 6 (27.3%) | ||
| Nerve root injury | 0 | 3 (13.6%) | ||
| Damage of envelope | 5 (26.3%) | 13 (59.1%) |
| |
|
| ||||
| Resection range | R0 | 16 (84.2%) | 12 (54.5%) |
|
| R1 | 3 (15.7%) | 10 (45.5%) | ||
|
| ||||
| Titanium mesh subsidence | 8 (42.1%) | 9 (40.9%) | ||
|
| ||||
| Recurrence | 3 (15.7%) | 5 (22.7%) | ||
|
| ||||
| Oncological status | Death of dyscrasia | 1 (5.2%) | 1 (4.5%) | |
| Death of complications | 5 (26.3%) | 8 (36.4%) | ||
| No evidence of disease | 13 (68.4%) | 13 (59.1%) | ||
|
| ||||
| VAS | Preoperation | 6.1 ± 1.3 | 5.8 ± 1.2 | |
| 1 week postoperation | 2.3 ± 0.9 ( | 2.2 ± 0.7 ( | ||
| 6 months postoperation | 0.6 ± 0.7( | 1.6 ± 1.1 ( |
| |
|
| ||||
| ASIA | Preoperation | C : 4 D : 6 E : 9 | B : 1 C : 1 D : 6 E : 14 | |
| Postoperation | D : 1 E : 18( | D : 3 E : 19 | ||
|
| ||||
| Follow-up time (m) | 19 ± 10 | 23 ± 9 | ||
P1: the P1 value was obtained by comparing VAS scores before and 1 week after surgery. P2: the P2 value was obtained by comparing VAS scores 1 week and 6 months after surgery. P:the P value was obtained by comparing ASIA grades before and 6 months after surgery.